Researcher gene therapy - Hiring in process/Finished, not possible to apply

The research group of Molecular Geriatrics is located at the Rudbeck Laboratory and is closely linked to the memory clinic at the Uppsala University Hospital. Our research is focused on protein aggregation in neurodegenerative diseases. The research is conducted in collaboration with other research groups internationally and in Sweden, as well as with various pharmaceutical companies.

Job description: Parkinson's disease is the second most common neurodegenerative disease and is characterized by pathologically altered forms of the protein alpha-synuclein in different parts of the brain. The treatment, which is aimed at increasing the levels of the signal substance L-dopa, only relieves symptoms and is not aimed at the underlying disease process. There is therefore a great need to develop new therapies. One possibility may be to influence the formation of alpha-synuclein with new gene therapeutic methods. The gene encoding this protein, SNCA, may in rare cases be mutated, leading to the formation of either more protein, or an altered protein. However, the vast majority of cases are sporadic, but even for these there is evidence that increased expression of SNCA causes the disease. In an ongoing project, the research team is developing a gene editing method to reduce the formation of alpha-synuclein.

The researcher will carry out studies in which mutated or non-mutated forms of SNCA are expressed in cell and animal models of the disease. With CRISPR/Cas9, delivered by transfection or AAV-mediated transduction, the gene is inactivated. Sanger- and Next Generation sequencing are used to detect effects at the DNA level. With quantitative PCR RNA levels are examined and with Western blot and immunochemical methods the presence of proteins in cell preparations and tissues are studied. Various methods for evaluating cell functions are also used. The overall goal of the study is to contribute to the development of new treatment methods for Parkinson's disease. The work is carried out at Uppsala University (Rudbeck Laboratory).

Required qualifications: We welcome applications from highly motivated and enthusiastic candidates with a PhD and some years of research experience We are looking for a highly motivated and enthusiastic researcher with a doctorate in the biomedical field and with postdoctoral research experience in the field of gene therapy. Previous experiences in gene editing techniques, production and utilization of AAV vectors as well as cell culture, transfection, and animal handling are required. The applicant also needs to have a good knowledge of written and spoken English.

Application: The application should contain a cover letter (maximum 1 page) describing the applicant’s research interests, an updated CV with a list of publications, copies of diplomas and certificates of higher academic degrees as well as contact details (name, e-mail, phone number) of two referees.

Selection process: Selection of candidates is based on qualifications, research experience, and personal suitability.

Salary: Individual salary

Starting date: 02-08-2021 or as otherwise agreed

Type of employment: Temporary position until 30-06-2022

Scope of employment: 100 %

For further information about the position please contact: professor Martin Ingelsson, martin.ingelsson@pubcare.uu.se

Please submit your application no later than June 16th 2021, UFV-PA 2021/2358.